Aimmune's lead candidate successful in late-stage peanut allergy study; shares ahead 19% premarket [Seeking Alpha]
AIMMUNE THERAPEUTICS (AIMT)
Last aimmune therapeutics earnings: 2/27 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aimmune.com/corporate-profile
Company Research
Source: Seeking Alpha
Aimmune's lead candidate successful in late-stage peanut allergy study; shares ahead 19% premarketA 496-subject Phase 3 clinical trial,PALISADE, assessing Aimmune Therapeutics' (NASDAQ:AIMT) lead candidate AR101 in with highly sensitive peanut allergymet the primary endpoint of demonstrating desensitization at month 12.76.6% of participants treated with AR101 tolerated 300 mg of peanut protein compared to 8.1% for placebo (pU.S. marketing application by year-end followed by a European application in 2019.Fast Track- and Breakthrough Therapy-taggedAR101 is an orally administered biologic that desensitizes patients with peanut allergy.Shares are up19% premarket on modestly higher volume.See all stocks on the move »Now read:U.S. Biotech/Pharma Sector Daily Observations Letter: February 14, 2018, Featuring DBV Technologies »
Show less
Read more
Impact Snapshot
Event Time:
AIMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AIMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AIMT alerts
High impacting AIMMUNE THERAPEUTICS news events
Weekly update
A roundup of the hottest topics